Access to this article is restricted until 12 months after publication by request of the publisher. Restriction lift date: 2025-11-29
Computed tomography morphomics and antifibrotic therapy in idiopathic pulmonary fibrosis
Loading...
Files
Date
2024-11-29
Authors
O'Mahony, A. T.
Waldron, M. G.
Henry, P. J.
Shet, Sahil
O'Regan, P. W.
Bennett, D. M.
Ryan, D. J.
Maher, M. M.
Henry, M. T.
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier Ltd.
Published Version
Abstract
AIM: Idiopathic pulmonary fibrosis (IPF) is a debilitating and fatal lung disease. Changes in body composition potentially correlate with outcomes in patients with IPF. MATERIALS AND METHODS: Patients with IPF on antifibrotic treatment attending a single institution were identified and retrospectively evaluated (n=84). Three groups were formed based on antifibrotic treatment: pirfenidone group, nintedanib group and pirfenidone-nintedanib switch group. Morphomic analysis of muscle quantity (cross-sectional area in cm2) and quality (density in Hounsfield Units) on thoracic computed tomography (CT) was performed using a web-based morphomic segmentation tool. Bilateral erector spinae and pectoralis muscles were measured at pre-defined vertebral levels. RESULTS: All three treatment groups showed a statistically significant decline in forced vital capacity (FVC), diffusion capacity of the lung for carbon monoxide (DLCO), pectoral muscle cross sectional area (PMA), and erector spinae muscle cross-sectional area (ESMA). Muscle density did not change significantly. Differences existed in analytic morphomics between treatment groups. Patients with a pretreatment body mass index (BMI) below 30 were found to have a significantly greater loss of PMA when treated with nintedanib instead of pirfenidone. FVC and DLCO did not differ between treatment groups. CONCLUSION: There were no direct correlations between pulmonary function and morphomic parameters in our entire group of IPF patients. However, between different treatment groups, the rate of muscle bulk loss differed. This is an important consideration for clinicians when deciding on an antifibrotic agent of choice.
Description
Keywords
Pulmonary function , Idiopathic pulmonary fibrosis , Muscle bulk loss , Antifibrotic agent
Citation
O'Mahony, A. T., Waldron, M. G., Henry, P. J., Shet, S., O'Regan, P. W., Bennett, D. M., Ryan, D. J., Maher, M. M. and Henry, M. T. (2025) 'Computed tomography morphomics and antifibrotic therapy in idiopathic pulmonary fibrosis', Clinical Radiology, 81, 106759 (8pp). https://doi.org/10.1016/j.crad.2024.106759